KRSA.US Korsana Biosciences, Inc.
- Market cap
- USD 1.44B
- P/E
- -
- P/B
- 3.66x
- ROE
- -17.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KRSA.US undervalued?
Graham numberThe Graham number of Korsana Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Korsana Biosciences, Inc. fundamental analysis
No fundamental analysis for Korsana Biosciences, Inc. yet.
Korsana Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an …
Full company profileKorsana Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Korsana Biosciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 4.51M | 2.30M | 3.32M | 297K | - | 2.00M | 2.07M | - |
| Gross Profit | -2.17M | -1.75M | -1.53M | -90.6M | -54.1M | 3.32M | -5.28M | -1.32M | 2.00M | 2.07M | - |
| Operating Income | -63.6M | -93.9M | -115M | -125M | -81.3M | -55.2M | -18.5M | -13.0M | -3.63M | -4.97M | -71.0M |
| EBITDA | -61.4M | -92.2M | -114M | -122M | -80.6M | -53.8M | -18.2M | -9.58M | -3.06M | -3.53M | -70.9M |
| Net Income | -63.6M | -93.9M | -115M | -123M | -77.8M | -51.6M | -44.1M | -5.26M | -3.06M | -3.53M | -68.5M |
| EPS | -325 | -482 | -591 | -629 | -358 | -185 | -20 | -2.25 | -0.61 | -0.70 | -506 |
| Balance Sheet | |||||||||||
| Total Assets | - | 5.47M | 7.40M | 186M | 115M | 59.3M | 18.1M | 13.4M | 9.58M | 9.99M | 462M |
| Total Liabilities | - | 14.0M | 17.8M | 88.7M | 55.9M | 11.1M | 7.63M | 2.09M | 725K | 900K | 45.6M |
| Shareholders' Equity | - | -8.57M | -10.4M | 97.7M | 59.5M | 48.2M | 10.5M | 11.3M | 8.85M | 9.09M | 392M |
| Cash & Short-term Investments | - | - | - | 97.6M | 54.4M | 54.0M | 13.4M | 7.57M | 3.23M | 3.24M | 456M |
| Total Debt | - | - | - | 73.9M | 45.7M | - | - | - | - | - | 1.27M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -49.9M | -81.2M | -97.5M | -102M | -72.5M | -36.5M | -40.6M | -21.2M | -4.33M | -3.31M | -65.9M |
| Capital Expenditure | 1.45M | 1.40M | 3.44M | 6.89M | 1.52M | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 572K |
| Free Cash Flow | -51.3M | -82.6M | -101M | -109M | -74.0M | -36.5M | -40.6M | -21.2M | -4.33M | -3.31M | -66.3M |
| Ratios | |||||||||||
| ROE | - | - | - | -125.9% | -130.8% | -107.0% | -421.7% | -46.6% | -34.5% | -38.8% | -17.5% |
| ROA | - | -1,717.0% | -1,557.2% | -66.0% | -67.4% | -87.0% | -243.8% | -39.4% | -31.9% | -35.3% | -14.8% |
| Net Profit Margin | - | - | - | -2,729.3% | -3,388.6% | -1,555.6% | -14,841.1% | - | -152.9% | -170.1% | - |
| Debt to Equity | - | - | - | 0.76x | 0.77x | - | - | - | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Korsana Biosciences, Inc. dividends
Korsana Biosciences, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Sep 9, 2026.
Who owns Korsana Biosciences, Inc.
- Insiders 5.11%
- Institutions 63.56%
- Public & others 31.33%
- Shares outstanding 45.5M
- Free float 3.44M
Top funds holding KRSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 218K | 0.48% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 65.4K | 0.14% | +330.03% | Sep 2026 |
| Fidelity Growth Company K6 | 60.7K | 0.13% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 57.3K | 0.13% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 43.3K | 0.10% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 41.3K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 37.5K | 0.08% | 0.00% | Aug 2026 |
| Fidelity VIP Health Care Initial | 24.1K | 0.05% | +288.06% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 15.1K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 9.90K | 0.02% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 4.98K | 0.01% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite ETF | 3.08K | 0.01% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 2.47K | 0.01% | -85.77% | Sep 2026 |
| LUX IM Global Medtech HX | 2.35K | 0.01% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 481.00 | 0.00% | -85.71% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 474.00 | 0.00% | 0.00% | Oct 2026 |
| DFA U.S. Vector Equity I | 470.00 | 0.00% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 322.00 | 0.00% | -85.75% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 312.00 | 0.00% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 106.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding KRSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sanofi | 1.99M | 4.38% | 0.00% | Sep 2026 |
| General Atlantic Llc | 1.37M | 3.00% | 0.00% | Sep 2026 |
| Spruce Street Capital LP | 339K | 0.74% | 0.00% | Sep 2026 |
| NEXTBio Capital Management LP | 175K | 0.39% | 0.00% | Sep 2026 |
Korsana Biosciences, Inc. company profile
- Company name
- Korsana Biosciences, Inc.
- Ticker
- KRSA.US
- Exchange
- USA Stocks
- Listed since
- Apr 2, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 221 Crescent Street, Waltham, MA, United States, 02453
- Phone
- 781 516 2325
- Website
- korsana.com
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
Korsana Biosciences, Inc. management
5- Dr. Jonathan Violin M.B.A., Ph.D.President, CEO, Secretary & Director · born 1975
- Dr. Mark Joseph Vignola Ph.D.Chief Financial Officer · born 1978
- Dr. Gan Wei Ph.D.Chief Technical Officer
- Dr. Matthew Leoni M.D.Chief Medical Officer
- Mr. Kyle Breidenstine CPA, M.B.A.Senior Vice President of Finance & Treasurer